The term cerebral small vessel disease (SVD) refers to the sum of all pathological processes affecting the small vessels of the brain. Although SVD has been recognized as a leading cause of age-related cognitive decline, its underlying mechanisms remain unknown. Moreover, therapeutic options for SVD patients are still limited, primarily because relevant disease models that can guide target identification and drug discovery are lacking.
Sound Wave Innovation Co. Ltd. seeks patent protection for a method of using an ultrasonic device which transmits non-converging ultrasonic energy to the brain for the treatment of dementia, including mild Alzheimer’s-type dementia and mild cognitive impairment.
Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.
Researchers at Tufts University and University of Houston System have identified receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) and/or nucleotide-binding oligomerization domain-containing protein 2 (NOD2) inhibitors reported to be useful for the treatment of multiple sclerosis.
Researchers from West China Hospital of Sichuan University presented data from a study that aimed to investigate the associations between serum cystatin C (CysC) levels and the progression and survival of patients with amyotrophic lateral sclerosis (ALS).
Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers.
Just over a year since the last anti-nerve growth factor (NGF) antibody program was axed, the target is poised for a revival, with Levicept Ltd. announcing it has completed recruitment to a phase II trial of LEVI-04 in the control of chronic pain caused by osteoarthritis.
All treatment groups in Vertex Pharmaceuticals Inc.’s phase II study of the non-opioid VX-548 showed meaningful reductions in pain from baseline in treating diabetic peripheral neuropathy (DPN), pointing the company toward pivotal phase III studies and prompting analysts to applaud enthusiastically.
With an urgent need to create new technologies to improve the detection of traumatic brain injuries (TBI), researchers from the University of Birmingham, U.K., have designed and developed a diagnostic device that can detect TBI by shining a laser into the eye.
RSS
